Quantcast

Latest drug discovery Stories

2014-06-10 08:31:42

DOYLESTOWN, Pa., June 10, 2014 /PRNewswire/ -- On June 2, 2014 Makindus, Inc. a specialty pharmaceutical company, received orphan drug designation for their lead product MI-100 from the U.S. Food and Drug Administration Office of Orphan Products Development for the treatment of Stargardt's Disease. "The FDA's approval of our orphan drug designation application for MI-100 to treat Stargardt's disease is a key milestone for the company and we look forward to initiating our Phase 3...

2014-06-06 23:01:25

Inspiring patient advocates collaborate with those who create and regulate therapies. Washington, DC (PRWEB) June 06, 2014 The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson’s disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars. A patient with a rare ailment that went undiagnosed for 40 years works hand in hand with researchers to...

2014-06-06 16:23:27

ADDF Harrington Scholars selected to receive funding and project management to support recent discoveries that may lead to new therapeutics for the treatment of Alzheimer's disease CLEVELAND, June 6, 2014 /PRNewswire/ -- Researchers from The Ohio State (Columbus) and Emory (Atlanta) Universities will be the first recipients of drug discovery funding and innovation support from a new partnership between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute (HDI)...

2014-06-06 08:23:47

RnRMarketResearch.com adds a 2014 survey report on "Epigenetic Modification Screening technologies that summarizes trends and results of HTStec's 3rd industry-wide global web-based benchmarking survey carried out in May 2014. DALLAS, June 6, 2014 /PRNewswire-iReach/ -- The main objectives of " Epigenetic Modification Screening Trends 2014 " market study was to comprehensively document current practices and preferences in epigenetic modification assays, and to understand future user...

2014-06-05 23:09:14

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing Geneva, Switzerland (PRWEB) June 05, 2014 Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One...

2014-06-05 23:01:02

Leading research and industry experts discuss the role of researchers and the opportunities and challenges of a new monitoring model. Washington, DC (PRWEB) June 05, 2014 In a drug development landscape where clinical trial sponsors must find ways to gain value from limited research budgets, risk-based monitoring — the strategic assessment of risk when creating and conducting trials — is emerging as a model for reducing the complexity of a study while enhancing patient safety and...

2014-06-04 23:08:13

A new data standard for multiple sclerosis (MS) has been released by the Clinical Data Interchange Standards Consortium (CDISC), the leading global standards organization for clinical research. When used together with the foundational CDISC clinical data standard, this therapeutic area standard allows clinical research data from multiple MS trials to be grouped for reporting, analysis, and regulatory submissions. Austin, TX; New York, NY and Tucson, AZ (PRWEB) June 04, 2014 A new data...

2014-06-04 23:05:47

Sessions to provide international perspectives and reveal new collaborative approaches. Washington (PRWEB) June 04, 2014 The world’s foremost drug industry regulators will address urgent topics surrounding regulatory guidance, such as the challenges and future of the Food and Drug Administration (FDA) and its international counterparts, at the DIA 2014 50th Annual Meeting to be held at the San Diego Convention Center from June 15 to 19. “We are honored and excited to have the...

2014-06-04 16:26:01

FDA Removes Clinical Hold on Phase 2 Trial (Study 202) SAN DIEGO, June 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review...

2014-06-03 23:04:51

Vala Sciences’ Kinetic Image Cytometer (KIC) was utilized by collaborator and Scientific Advisory Board member, Dr. Mark Mercola, and a team of researchers from the University of California, San Diego, Sanford-Burnham Medical Research Institute, and the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, to discover a powerful new player in the onset and progression of heart failure. San Diego, CA (PRWEB) June 03, 2014 Vala Sciences’ Kinetic Image Cytometer...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related